Annual SG&A
$83.41 M
+$14.65 M+21.31%
31 December 2023
Summary:
BioXcel Therapeutics annual selling, general & administrative expenses is currently $83.41 million, with the most recent change of +$14.65 million (+21.31%) on 31 December 2023. During the last 3 years, it has risen by +$59.11 million (+243.24%). BTAI annual SG&A is now at all-time high.BTAI Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$7.68 M
-$1.77 M-18.70%
30 September 2024
Summary:
BioXcel Therapeutics quarterly selling, general & administrative expenses is currently $7.68 million, with the most recent change of -$1.77 million (-18.70%) on 30 September 2024. Over the past year, it has dropped by -$16.66 million (-68.44%). BTAI quarterly SG&A is now -70.30% below its all-time high of $25.87 million, reached on 30 June 2023.BTAI Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$2.47 B
-$71.00 M-2.96%
30 September 2024
Summary:
BioXcel Therapeutics TTM selling, general & administrative expenses is currently -$2.47 billion, with the most recent change of -$71.00 million (-2.96%) on 30 September 2024. Over the past year, it has dropped by -$2.57 billion (-2717.64%). BTAI TTM SG&A is now -55473.33% below its all-time high of $94.47 million, reached on 30 September 2023.BTAI TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BTAI Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +21.3% | -68.4% | -2717.6% |
| 3 y3 years | +243.2% | -48.4% | -5014.8% |
| 5 y5 years | +1443.5% | +281.9% | -10000.0% |
BTAI Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +243.2% | -70.3% | at low | -245.1% | at low |
| 5 y | 5 years | at high | +1443.5% | -70.3% | +300.6% | -1636.0% | at low |
| alltime | all time | at high | >+9999.0% | -70.3% | +3593.8% | <-9999.0% | at low |
BioXcel Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $7.68 M(-18.7%) | $40.00 M(-29.4%) |
| June 2024 | - | $9.45 M(-28.8%) | $56.66 M(-22.5%) |
| Mar 2024 | - | $13.26 M(+38.1%) | $73.08 M(-12.4%) |
| Dec 2023 | $83.41 M(+21.3%) | $9.60 M(-60.6%) | $83.41 M(-11.7%) |
| Sept 2023 | - | $24.34 M(-5.9%) | $94.47 M(+8.4%) |
| June 2023 | - | $25.87 M(+9.7%) | $87.19 M(+9.4%) |
| Mar 2023 | - | $23.59 M(+14.2%) | $79.69 M(+15.5%) |
| Dec 2022 | $68.76 M(+26.8%) | $20.66 M(+21.2%) | $69.02 M(+11.4%) |
| Sept 2022 | - | $17.05 M(-7.2%) | $61.96 M(+3.6%) |
| June 2022 | - | $18.38 M(+42.3%) | $59.79 M(+7.7%) |
| Mar 2022 | - | $12.92 M(-5.0%) | $55.51 M(+2.4%) |
| Dec 2021 | $54.23 M(+123.1%) | $13.61 M(-8.5%) | $54.23 M(+7.8%) |
| Sept 2021 | - | $14.88 M(+5.5%) | $50.32 M(+14.6%) |
| June 2021 | - | $14.10 M(+21.2%) | $43.89 M(+31.7%) |
| Mar 2021 | - | $11.64 M(+20.0%) | $33.31 M(+37.1%) |
| Dec 2020 | $24.30 M | $9.70 M(+14.7%) | $24.30 M(+47.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $8.45 M(+139.5%) | $16.52 M(+63.9%) |
| June 2020 | - | $3.53 M(+34.4%) | $10.08 M(+16.1%) |
| Mar 2020 | - | $2.63 M(+36.9%) | $8.68 M(+11.3%) |
| Dec 2019 | $7.80 M(+44.4%) | $1.92 M(-4.7%) | $7.80 M(+8.7%) |
| Sept 2019 | - | $2.01 M(-5.5%) | $7.18 M(+11.0%) |
| June 2019 | - | $2.13 M(+22.0%) | $6.47 M(+11.5%) |
| Mar 2019 | - | $1.75 M(+34.7%) | $5.80 M(+7.3%) |
| Dec 2018 | $5.40 M(+192.6%) | $1.29 M(-0.2%) | $5.40 M(+3.7%) |
| Sept 2018 | - | $1.30 M(-11.3%) | $5.21 M(+23.8%) |
| June 2018 | - | $1.46 M(+8.5%) | $4.21 M(+40.9%) |
| Mar 2018 | - | $1.35 M(+22.5%) | $2.99 M(+61.7%) |
| Dec 2017 | $1.85 M(+156.2%) | $1.10 M(+269.1%) | $1.85 M(+147.3%) |
| Sept 2017 | - | $298.00 K(+23.7%) | $747.00 K(+66.4%) |
| June 2017 | - | $241.00 K(+15.9%) | $449.00 K(+115.9%) |
| Mar 2017 | - | $208.00 K | $208.00 K |
| Dec 2016 | $721.00 K | - | - |
FAQ
- What is BioXcel Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for BioXcel Therapeutics?
- What is BioXcel Therapeutics annual SG&A year-on-year change?
- What is BioXcel Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for BioXcel Therapeutics?
- What is BioXcel Therapeutics quarterly SG&A year-on-year change?
- What is BioXcel Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for BioXcel Therapeutics?
- What is BioXcel Therapeutics TTM SG&A year-on-year change?
What is BioXcel Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of BTAI is $83.41 M
What is the all time high annual SG&A for BioXcel Therapeutics?
BioXcel Therapeutics all-time high annual selling, general & administrative expenses is $83.41 M
What is BioXcel Therapeutics annual SG&A year-on-year change?
Over the past year, BTAI annual selling, general & administrative expenses has changed by +$14.65 M (+21.31%)
What is BioXcel Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of BTAI is $7.68 M
What is the all time high quarterly SG&A for BioXcel Therapeutics?
BioXcel Therapeutics all-time high quarterly selling, general & administrative expenses is $25.87 M
What is BioXcel Therapeutics quarterly SG&A year-on-year change?
Over the past year, BTAI quarterly selling, general & administrative expenses has changed by -$16.66 M (-68.44%)
What is BioXcel Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of BTAI is -$2.47 B
What is the all time high TTM SG&A for BioXcel Therapeutics?
BioXcel Therapeutics all-time high TTM selling, general & administrative expenses is $94.47 M
What is BioXcel Therapeutics TTM SG&A year-on-year change?
Over the past year, BTAI TTM selling, general & administrative expenses has changed by -$2.57 B (-2717.64%)